News 2020-05-13
Porton Shanghai Formulation R&D Center Launched Construction
Shanghai, China, May 13, 2020 - Porton Pharmatech Co. ,Ltd. (Porton Pharmatech), a subsidiary of Porton Pharma Solutions Ltd. (Porton, Stock Code: 300363), today announced the commencement of construction of its Shanghai R&D Center, which would be Porton’s third formulation lab site that has been constructed since 2019. It has previously started design and construction of two other formulation labs based in Chongqing, China and New Jersey，USA.
Others
More
News 2026-07-08
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
News 2026-07-03
Porton Delivers Dual-Payload ADC IND, Advancing Next-generation Conjugate Drug Development
Porton One-stop Biologics and Conjugates CDMO Platform successfully completed the full-cycle delivery of process development and GMP IND clinical sample manufacturing for a dual-payload ADC.
